WAM
REGN icon

Wakefield Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Wakefield Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,751
Closed -$3M – 191
2021
Q4 		$3M Buy
+4,751
New +$2.92M 1.04% 29

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wakefield Asset Management's REGN Position: Q1 2022 in Review

Wakefield Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 4,751 shares — an estimated $3M sold.

Wakefield Asset Management first reported a position in REGN in Q4 2021 and held it in 1 quarter. The position peaked at $3M in Q4 2021. 1,094 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

  • Wakefield Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Wakefield Asset Management sold 4,751 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $3M.
  • Wakefield Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Wakefield Asset Management's Regeneron Pharmaceuticals position peaked at $3M in Q4 2021.
  • 1,094 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Wakefield Asset Management's 13F filing for Q1 2022, filed 2 May 2022.